Additionally, the research revealed that the treatment with SGLT2 inhibitors led to an augmentation in the phosphorylation of AMP-activated protein kinase (AMPK) and a reduction in the phosphorylation of 70 kDa ribosomal protein S6 kinase 1 (p70S6K1) within breast cancer cells [85]. The gene discussed is RPS6KB1; the disease is breast carcinoma.